Oral Cromolyn Sodium 

• Product Class: Polar Organic

• Indication: Treatment of asthma and allergy

• Ownership: EMIS

• Status: early Phase II patient testing in allergy patients

• Upcoming CY02 Milestones: Additional Phase II studies in asthma and sickle cell patients

• Product Profile: Excellent safety profile; cromolyn’s clinical effectiveness has been demonstrated in a wide variety of asthma and allergy indications

• High Margin Opportunity:
  • Asthma affects an estimated 15 million Americans;  direct health care costs of $8.1 billion annually
  • Underserved Market

Previous slide

Next slide

Back to first slide

View graphic version